Back to today’s briefing

Story perspectives

Semaglutide Cuts Dementia Risk in Diabetics, Study Finds

8/5/2025

49 6

Summary

Story summary

A groundbreaking study from Case Western Reserve School of Medicine reveals that semaglutide, a drug for diabetes and weight loss, could significantly reduce dementia risk in type 2 diabetes patients. Analyzing data from 1.7 million people, researchers discovered that users of semaglutide experienced lower rates of Alzheimer's-related dementia, especially among older adults and women. More clinical trials are on the horizon.

1 of 1

Story summary

A groundbreaking study from Case Western Reserve School of Medicine reveals that semaglutide, a drug for diabetes and weight loss, could significantly reduce dementia risk in type 2 diabetes patients. Analyzing data from 1.7 million people, researchers discovered that users of semaglutide experienced lower rates of Alzheimer's-related dementia, especially among older adults and women. More clinical trials are on the horizon.